Saratov JOURNAL of Medical and Scientific Research

Comparison of clinical results of pharmaceutical and surgical therapy in patients with severe chronic heart failure

Year: 2016, volume 12 Issue: №2 Pages: 145-156
Heading: cardiac surgery Article type: Review
Authors: Kotsoeva О.Т.
Organization: North-Caucasian Multidisciplinary Medical Center
Summary:

The aim of the presented paper is a meta-analysis of clinical studies on the comparative effectiveness of pharmaceutical therapy and surgical treatment such as cardiac resynchronization therapy (CRT), cardiac resynchronization therapy with cardioversion-defibrillation (CRT-D), circulatory support system and heart transplantation in patients with severe chronic heart failure (CHF). Material and Methods. Results of 41 clinical studies (29799 patients with severe CHF) were included in a meta-analysis. Data search was conducted in the following databases: Medline, Medscape, Pubmed, and websites dedicated to clinical research (National Institutes of Health, Clinical Center, ClinicalStudyResults.org, ClinicalTrials.gov). Results. As compared with pharmaceutical therapy, surgical treatment of severe CHF is better to reduce fatal risk, incidence of decompensation of CHF, frequency of cardiac arrhythmias, the need to perform or re-perform heart transplantation. It is also shown that CRT better reduced the mortality from progression of heart failure than heart transplantation. Both pharmaceutical therapy and surgical treatment improved functional class of CHF and quality of patients' life, but does not affect the left ventricular ejection fraction. Conclusion. It was found out that there was a number of significant advantages of surgical treatment of severe CHF, compared with pharmaceutical therapy. However, it is still a number of unresolved issues (particularly in relation to heart transplantation) on the effectiveness comparing pharmaceutical and surgical therapies of severe CHF

Bibliography:
1. Mareev V.Yu., Ageev F.T., Arutyunov G.P., et al. National guidelines for diagnosis and treatment of CHF (second revision). Zhurnal Serdechnaya Nedostatochnost' 2007; 8 (1): 4-41
2. Mareev V.Yu., Ageev F.T., Arutyunov G.P., et al. National guidelines for diagnosis and treatment of CHF (third revision). Zhurnal Serdechnaya Nedostatochnost' 2010; 11 (1): 3-62
3. Mareev V.Yu., Ageev F.T., Arutyunov G.P., et al. National guidelines for diagnosis and treatment of CHF (fourth revision). Zhurnal Serdechnaya Nedostatochnost' 2013; 14 (7): 379-472
4. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33 (14): 1787-1847
5. National Clinical Guidelines Centre (UK). Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care (NICE Clinical Guidelines, No. 108). London: Royal College of Physicians (UK), 2010; 646 p.
6. Kiselev A.R., Shvartz V.A., Vodolazov A.M., etal. Organization-and-technological model of medical care delivered to patients with chronic heart failure. Cardio-IT 2014; 1: 0304
7. Posnenkova О.М., Kiselev A.R., Popova Y.V., et al. Methodology of clinical measures of healthcare quality delivered to patients with cardiovascular diseases. Cardio-IT 2014; 1 (1): 0103
8. Oshchepkova E.V., Dovgalevsky P.Ya., Gridnev V.I., et al. Key data elements and definitions of the Russian registry of patients with arterial hypertension, coronary artery disease and chronic heart failure. Cardio-IT 2014; 1 (2): 0202
9. Oshchepkova E.V., Dovgalevsky P.Ya., Boytsov S.A., et al. User guide of Russian registry of patients with arterial hypertension, coronary artery disease and chronic heart failure. Cardio-IT 2014; 1 (2): 0204
10. Posnenkova О.М., Kiselev A.R., Korotin A.S., etal. Public report on quality of care delivered to patients with stable coronary artery disease and chronic heart failure in 2013: the data from Saratov Registry of coronary artery disease and chronic heart failure. Cardio-IT 2014; 1 (4): 0402
11. Korotin A.S., Posnenkova О.М., Kiselev A.R., et al. Implementation of recommended measures in patients with chronic heart failure: the data from 2014 Russian registry. Cardio-IT 2015; 2 (1): e0104
12. Correale М, Totaro A, Ferraretti A, et al. Additional Prognostic Value of EAS index in predicting the occurrence of rehospitalizations in chronic heart failure: data from the Daunia Heart Failure Registry. Eur J Clin Invest 2015; 45 (10): 1098-1105
13. De Sutter J, Pardaens S, Audenaert T, et al. Clinical characteristics and short-term outcome of patients admitted with heart failure in Belgium: results from the BIO-HF registry. Acta Cardiol 2015; 70 (4): 375-385
14. Li SJ, Sartipy U, Lund LH, etal. Prognostic Significance of Resting Heart Rate and Use of p-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry. Circ Heart Fail 2015; 8 (5): 871-879
15. Bokeria O.L., Kuular A.M. Influence of low-intensity electromagnetic fields on endothelial function in patients with chronic heart failure. Saratov Journal of Medical Scientific Research 2014; 10 (1): 86-92
16. Shvarts Yu.G., Martynovich T.V., Akimova N.S., Fedotov E.A. Role of genetic factors in development of CHF. Russian Heart Failure Journal 2013; 14 (6): 369-376
17. Kiselev A.R., Gridnev V.I., Kolizhirina О.М., et al. Assaysment of the state of myocardial contractility based on analysis of heart rate variability during exercise tests. Kardiologiia 2005; 45 (10): 23-26
18. Akimova N.S., Zuev V.V., Martinovich T.V., et al. Correlations between severity of chronic heart failure and condition of central nervouse system in patients with ischemic heart disease. Fundamental Research 2011; (11-3): 467-471
19. Martynovich T.V., Akimova N.S., Fedotov E.A., Schwartz Y.G. Polymorphism of genes associated with increased cardiovascular risk and cognitive function in patients with chronic heart failure and in healthy persons: the pilot study. Russian Open Medical Journal 2015; 4 (1): e0102
20. Ayvazyan G.G., Alekyan B.G., Buziashvili Yu.l., et al. Immediate and long-term outcomes of PCI in patients with chronic ischemic heart disease and left ventricular dysfunction (ejection fraction less than 30%). Byulleten' Nauchnogo Tsentra: Serdechno-Sosudistoy Khirurgii imeni A. N. Bakuleva RossiyskoyAcademii Meditsinskikh Nauk. Serdechno-sosudistye zabolevaniya 2015; 16 (S6): 162
21. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002; 346: 1845-1853
22. Anyanwu AC, Rogers CA, Murday AJ. Intrathoracic organ transplantation in the United Kingdom 1995-99: results from the UK cardiothoracic transplant audit. Heart 2002; 87: 449-454
23. Hertz M, Taylor D, Trulock E, et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report-2002. J Heart Lung Transplant 2002; 21: 950-970
24. Kuznetsov V.A. Cardiac resynchronization therapy: selected issues. Moscow, 2007; 128 p. Russian (Кузнецов В. А. Сердечная ресинхронизирующая терапия: избранные вопросы. Москва, 2007; 128 с)
25. Revishvili A.Sh. Cardiac resynchronization therapy in the treatment of chronic heart failure. Vestnik Aritmologii 2007; (48): 47-58
26. Мс Alister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297: 2502-2514
27. Zabarovskaja S., Gadler F., Braunschweig F., et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace 2012; 14 (8): 1148-1155
28. Petrosyan AD. The impact of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices on myocardial contractility in patients with chronic heart failure patients. Bulletin of Medical Internet Conferences 2014; 4 (3): 240-243
29. Stupakov S.I., Kislitsina O.N., Melikulov A.Kh. Cardiac resynchronization therapy in patients with chronic heart failure and permanent atrial fibrillation (clinical case). Bulletin of Medical Internet Conferences 2014; 4 (3): 218-220
30. Kotsoeva О.Т. Features of cardiac resynchronization therapy after heart transplantation. Bulletin of Medical Internet Conferences 2015; 5 (11): 1393-1395
31. Le TG, Bokeriya LA, Bokeriya OL, et al. The safety of endometrial regenerative cells in the treatment of patients with chronic heart failure. Byulleten' Nauchnogo Tsentra Serdechno-Sosudistoy Khirurgii imeni A. N. Bakuleva Rossiyskoy Academii Meditsinskikh Nauk: Serdechno-sosudistye zabolevaniya 2012; 13 (S6): 187
32. Kotsoeva О.Т., Bockeria O.L. Analysis of long-term results of medical and surgical treatment of patients with severe chronic heart failure. Klinicist 2016; 10 (1): 13-18
33. Kotsoeva О.Т. Comparison of long-term efficacy of medical therapy to surgical methods of treatment (cardiac resynchronization therapy and heart transplantation) in patients with severe chronic heart failure: results of a five-year observation. Bulletin of Medical Internet Conferences 2016; 6 (6): 833-835
34. Packer М, Lee WH, Yushak М, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315: 847-853
35. Bussmann WD, Storger H, Hadler D, et al. Long-term treatment of severe chronic heart failure with captopril: a double-blind, randomized, placebo-controlled, long-term study. J Cardiovasc Pharmacol 1987; 9 (2): 50-60
36. Kassis E, Amtorp O. Cardiovascular and neurohumoral postural responses and baroreceptor abnormalities during a course of adjunctive vasodilator therapy with felodipine for congestive heart failure. Circulation 1987; 75: 1204-1213
37. Kassis E, Amtorp O, Waldorff S, Fritz-Hansen P. Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress. Br Heart J 1987; 53: 505-511
38. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Result of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The New England Journal of Medicine 1987; 316(23): 1429-1435
39. Goldberg AD, Nicklas J, Goldstein S. Effectiveness of imazodan for treatment of chronic congestive heart failure. The Imazodan Research Group. Am J Cardiol 1991; 68 (6): 631 -636
40. Lechat P, Boutelant S, Komajda M, et al. Pilot study of cardiovascular effects of nebivolol in congestive heart failure. Drug Investigation 1991; 3 (1, Suppl.): 69-81
41. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of milrinone on mortality in severe chronic heart failure. The New Eng Journal of Medicine 1991; 21: 1468-1475
42. Ghose JC, Chakraborty S, Mondal M, Bhandari B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. J Assoc Physicians India 1993; 41 (5): 269-271
43. CIBIS Investigators and Committees. A Randomized Trial of beta-Blockade in Heart Failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90 (4): 1764-1773
44. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators. Br Heart J 1994; 72 (3): 226-230
45. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23 (4): 943-950
46. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. JACC 1995; 26 (2): 438-445
47. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92: 1499-1506
48. Lubsen J, Chadha DR, Yotof YT, Swedberg К Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am J Cardiol 1996; 77 (14): 1191-1196
49. Packer M, O'Connor CM, Ghali JK. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114
50. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997; 3 (3): 173-179
51. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349 (9057): 971-977
52. Conn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998; 339 (25): 1810-1816
53. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet 1999; 353 (9146): 9-13
54. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin ii receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-992
55. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344 (22): 1659-1667
56. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344 (12): 873-880
57. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345 (20): 1435-1443
58. AuricchioA, StellbrinkC, SackS, etal. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-2033
59. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23: 1780-1787
60. Leclerq C, Cazeau S, Lellouche D, et al. Upgrading from right ventricular pacing to biventricular pacing in previously paced patients with advanced heart failure: a randomized controlled study. Eur Heart J 2003; 24 (Suppl. Aug/Sept): 364A
61. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348 (14): 1309-1321
62. Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 2003; 289: 2685-2694
63. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150
64. Cabell CH,Trichon BH, Velazquez EJ.etal. Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. Am Heart J 2004; 147(1): 151-157
65. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-1549
66. Woo GW, Petersen-Stejskal S, Johnson JW, et al. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the MIRACLE study. J Interv Card Electrophysiol 2005; 12: 107-113
67. Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) Nrial/ COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail 2006; 6: 276-285
68. Kindermann M, Hennen B, Jung J, et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 2006; 47: 1927-1937
69. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007; 357 (24): 2461-2471
70. Feldman AM, Oren RM, Abraham WT, et al. Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J 2007; 154 (5): 861 -869
71. Cleland J. Predicting the long-term effects of cardiac-resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF Trial. J Am Coll Cardiol 2008; 52 (6): 438-445
72. Metra M, Eichhorn E, Abraham WT, et al. Effects of low-dose oral enoximone administration on mortality, morbidity and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebocontrolled, parallel group ESSENTIAL trials. European Heart Journal 2009; 30: 3015-3026
73. Wkstrom G. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. European Heart Journal 2009; 7: 782-788. 74. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309 (11): 1125-1135
75. Packer M, Carson P, Elkayam U. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2) Study. J Am Coll Cardiol HF 2013; 1: 308-314
76. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44 (9): 1834-1840
77. Tu RH, Peng RL, Zhong GQ, et al. A systematic review and meta-analysis on efficacy and safety of cardiac resynchronization therapy alone or in combination with implantable cardioversion defibrillation in patients with mild to severe heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2013; 41 (2): 161-170
78. Kantrowitz A, Haller JD. Symposium on human heart transplantation. Introduction. Am J Cardiol 1968; 22: 761
79. Eichhorn EJ. Prognosis determination in heart failure. Am J Med 2001; 110 (suppl 7A): 14s-36s
80. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361 (23): 2241-2251
81. Mcllvennan CK, Magid KH, Ambardekar AV, et al. Clinical outcomes after continuous-flow left ventricular assist device: a systematic review. Circ Heart Fail 2014; 7 (6): 1003-1013
82. Аnyanwu A, Treasure T. Prognosis after heart transplantation: transplants alone cannot be the solution for end stage heart failure. BMJ 2003; 326 (7388): 509-510
83. Theuns DA, Schaer BA, Soliman Ol, et al. The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality. Europace 2011; 13 (1): 62-69
84. Van Bommel RJ, Mollema SA, Borleffs CJ, et al. Impaired renal function is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2011; 57 (5): 549-555
85. Anghel D, Anghel R, Cordova F, et al. Preoperative arrhythmias such as atrial fibrillation: cardiovascular surgery risk factor. Biomed Res Int 2014; 2014: 584918
86. Arslan U, Memetoglu ME, Kutlu R, et al. Preoperative Hbalc level in prediction of short-term morbidity and mortality outcomes following coronary artery bypass grafting surgery. Russian Open Medical Journal 2015; 4 (2): e0204
87. Shakuri SK, Salekzamani Y, Taghizadieh A, et al. Pulmonary physiotherapy effect on patients undergoing open cardiac surgery. Russian Open Medical Journal 2014; 3 (3): 0306.

AttachmentSize
2016_02_145-156.pdf2.69 MB

No votes yet